Controlled document PF-017A
SX DUO Phase 1 Master Formula
Record identification
- Document ID
- PF-017A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-017A
PRODUCT FORMULA CARD
SIRIAM SX DUO – PHASE 1 (SACRAL RELEASE)
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-SX-001 |
| MF-017 |
| PF-017A |
| SX DUO – Phase 1 |
| S2–S5 + Coccyx |
| Sacral Release |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
The source fiche defines SX as a parasympathetic and neurodermal modulation system targeting S2–S5 and the coccyx, with Phase 1 focused on pelvic floor and coccygeal release.
| Description |
|---|
| Parasympathetic and neurodermal modulation of the sacral plexus and coccygeal projection |
| S2–S5 + Coccyx |
| Pelvic floor release, coccygeal unloading and parasympathetic regulation |
| Phase 1 – Release |
| Topical Magistral Cream |
2. MASTER FORMULA
The ingredient list reflects the uploaded Phase 1 magistral fiche, with the agreed SQMS standardisation for Vitamin E and Silicea.
| Code |
|---|
| Official Ingredient |
| Current |
| Proposed |
| Unit |
| PC-001 |
| Lanette Cream FNA |
| 65.00 |
| g |
| PC-002 |
| Aqua Purificata |
| 18.00 |
| g |
| SC-001 |
| Magnesium Chloride |
| 4.00 |
| g |
| SC-002 |
| MSM |
| 2.50 |
| g |
| OC-003 |
| Squalane |
| 4.00 |
| g |
| OC-002 |
| Jojoba Oil |
| 2.00 |
| g |
| SC-003 |
| D-Panthenol |
| 0.80 |
| g |
| SC-004 |
| Vitamin E Full Spectrum |
| 0.50 |
| g |
| BE-010 |
| Hypericum perforatum D6 |
| 0.50 |
| mL |
| HC-005 |
| Sepia officinalis D12 |
| 0.50 |
| mL |
| HC-006 |
| Staphysagria D8 |
| 0.50 |
| mL |
| BE-009 |
| Ruta graveolens |
| 0.40 |
| mL |
| BE-002 |
| Copaiba Oil |
| 0.30 |
| mL |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| 0.50 |
| g |
| PR-001 |
| Cosgard 221 |
| 0.70 |
| g |
3. MANUFACTURING WORKFLOW
Standard SQMS Lanette Workflow
Special note:
Pre-dissolve Staphysagria D8 granules in approximately 30% hydroalcoholic solution for 10–15 minutes before incorporation.
This preparation step is explicitly described in the source protocol.
4. QUALITY CONTROL
Standard SQMS Quality Control
5. BATCH RELEASE
Standard SQMS Batch Release
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Zone
Secondary Zone
Additional Zone
Additional Zone
Frequency
Treatment Phase
The application zones and protocol are defined in the magistral fiche.
| Value |
|---|
| S2–S5 |
| Entire sacrum |
| Coccyx |
| Upper intergluteal cleft |
| Ischial tuberosities |
| 1–2× daily |
| Weeks 1–2 |
Related documents
Platform modules